Insilico Medicine CEO Named a Highly Cited Researcher of 2022

Dr. Zhavoronkov

Global analytics company Clarivate™ has named Insilico Medicine Founder and CEO Alex Zhavoronkov (photo), PhD, as a Highly Cited Researcher for 2022. Fewer than 7,000, or about 0.1% of the world’s researchers receive this distinction, which is given to the select few researchers whose work is most frequently cited by their peers in 21 research fields. Dr. Zhavoronkov is very active in publishing, with the majority of research papers explaining the algorithms and methods behind the artificial intelligence (AI) software platforms that Insilico launched for the large community of scientists in the biopharmaceutical industry, including a paper on the AI target discovery platform PandaOmics and on Chemistry42, Insilico’s generative AI platform for chemistry. His recent paper in Nature Cell Death & Disease with researchers from University of Copenhagen and University of Chicago used PandaOmics to find novel biomarkers capable of stratifying cancer patients with different survival outcomes and then to identify novel targets for new therapeutics--an important step in the development of personalized cancer treatments. Other recent papers include a collaboration with Answer ALS and researchers from Johns Hopkins Medical School, Mayo Clinic, and Harvard Medical School that uncovered new therapeutic targets for ALS which was published in Frontiers in Aging Neuroscience, as well as the identification of dual-purpose targets for aging and disease using AI, published in the journal Aging.   

Login Or Register To Read Full Story